PACTR202207762785564
Other
Phase 3
Evaluation of the Efficacy, safety, and tolerability of Difluprednate 0.05% versus Prednisolone acetate 1% eye drops following uneventful phacoemulsification surgery
Suez Canal University Hospital0 sites800 target enrollmentJuly 4, 2022
ConditionsEye Diseases
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Eye Diseases
- Sponsor
- Suez Canal University Hospital
- Enrollment
- 800
- Status
- Other
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Age more than 50 years
- •2\.Patients diagnosed to have cataract, LOCS III cataract classification: NO \= 2 and NC \= 2\)
Exclusion Criteria
- •1\.Known sensitivity to any of the ingredients in this study medication
- •2\.History of glaucoma or ocular hypertension in the study eye
- •3\.Previous history of steroid\-induced increase of intraocular pressure (IOP)
- •4\.Previous ocular surgery
- •5\.history of uveitis
- •6\.Intraoperative complications as posterior capsule rupture
- •7\.Diabetic patients, Pregnancy, Autoimmune patients, and Single eyed patient.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
Phase 1
Evaluation of the efficacy, safety and tolerability of alisporivir for the treatment of hospitalised patients with infections due to SARS-CoV-2 (COVID-19).The study population will consist of adults (18-80 years old) hospitalised for =48 hours prior to randomisation with a diagnosis of COVID-19 based on symptoms onset and SARS-CoV-2 RT-PCR test positive from nasopharyngeal swab. Patients with ARDS or patients requiring mechanical ventilation at screening or randomisation will be excludedMedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2020-002295-13-FRAssistance Publique - Hôpitaux Paris100
Active, Not Recruiting
Phase 1
Evaluation of the therapeutic potential of a low-dose therapy with the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus.Patients with systemic lupus erythematosus (SLE) and increased disease activity refractory to standard therapies.MedDRA version: 18.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 18.0Level: PTClassification code 10067657Term: Systemic lupus erythematosus disease activity index increasedSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2013-001599-40-DECharité - Universitätsmedizin Berlin12
Completed
Phase 1
Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN)M32.1Systemic lupus erythematosus with organ or system involvementDRKS00004858Charité - Universitätsmedizin Berlin10
Active, Not Recruiting
N/A
Assessment of the safety, efficacy, tolerability and pharmacokinetics of PegIntron plus Rebetol in pediatric patients with chronic hepatitis C.EUCTR2004-000558-22-ITMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
Completed
Phase 3
A STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF LORNOXICAM SR 16mg Vs LORNOXICAM 8mg IN ADULT PATIENTS WITH OSTEOARTHRITIS OF THE HIP AND/OR KNEECTRI/2009/091/000297Glenmark Pharmaceuticals Ltd.210